Congo Starts Ervebo Ebola Vaccinations In Worst Outbreak On Record
The Democratic Republic of Congo launched an Ervebo Ebola vaccination campaign in Kisangani on Thursday, August 27, 2026, to protect health workers and contacts amid the country's deadliest outbreak on record.[1]
The World Health Organization cleared 70,000 Ervebo doses for use in Congo, with 50,000 slated for frontline health workers and 20,000 reserved for a clinical trial targeting Bundibugyo Ebola.[1] The campaign initially covers 14 health zones in Tshopo, Bas-Uele and Haut-Uele provinces and will prioritize immunizing health workers and people who had close contact with confirmed patients.[1] The outbreak has infected 5,713 people and killed 2,744 across six provinces, a confirmed-case fatality rate of about 48%.
On May 15, 2026, Congo declared its 17th Ebola outbreak after authorities identified the Bundibugyo virus in Mongbwalu health zone. The World Health Organization declared a Public Health Emergency of International Concern two days later as the virus spread across Ituri and neighboring provinces. By mid-August the epidemic had already surpassed the 2018-2020 Kivu outbreak totals, making it the country's deadliest Ebola epidemic.
Ervebo is licensed for the Zaire ebolavirus strain, not Bundibugyo, but studies show it generates cross-reactive antibody responses to Bundibugyo at lower levels than to Zaire. Health officials and partners pressed for compassionate-use deployment in early August because no licensed Bundibugyo vaccine exists, and they seek to slow transmission while clinical trials proceed. Social media posts and regional reporters highlighted Health Minister Samuel Roger Kamba's Kisangani launch and framed the arrival of doses as urgent international support.
The mainstream summary does not mention that the Democratic Republic of the Congo has experienced 16 Ebola outbreaks since 1976, with the previous largest outbreak occurring between 2018 and 2020, which involved 3,470 cases and 2,299 deaths. This context highlights the severity of the current outbreak, which has already surpassed those totals, making it imperative to understand the historical backdrop against which this latest crisis unfolds. Additionally, while the summary references the use of Ervebo for the Bundibugyo strain, it does not detail that previous Bundibugyo outbreaks were significantly smaller, with only 149 cases in Uganda in 2007 and 57 cases in DRC in 2012, underscoring the unprecedented scale of the current situation.
Moreover, the mainstream account lacks discussion on the structural factors exacerbating the outbreak, such as the impact of armed conflict and forced displacement, which have led to over 5 million internally displaced persons in the region. These conditions facilitate rapid virus transmission and hinder effective public health responses, including vaccination efforts. The International Committee of the Red Cross and other analyses emphasize that decades of conflict have eroded health infrastructure and trust, which are critical for managing outbreaks effectively. These insights reveal a deeper and more complex crisis than the mainstream summary implies, highlighting the urgent need for comprehensive interventions beyond vaccination alone.
Show source details & analysis (1 source)
📊 Relevant Data
The Democratic Republic of the Congo has recorded 16 Ebola outbreaks since 1976; the 2018-2020 Kivu outbreak (Zaire ebolavirus) was the largest prior, with 3,470 cases and 2,299 deaths.
Ebola virus disease – Democratic Republic of the Congo — World Health Organization
Prior Bundibugyo ebolavirus outbreaks were small: 149 cases and 37 deaths (CFR ~25%) in Uganda in 2007 and 57 cases and 29 deaths (CFR ~51%) in DRC in 2012.
Ebola Disease Distribution Map: Cases of Ebola Disease in Africa Since 1976 — Centers for Disease Control and Prevention
Ervebo (approved for Zaire ebolavirus) induced detectable cross-reactive antibody responses to Bundibugyo virus in serum samples from vaccinated individuals, though lower than responses to the homologous Zaire virus.
Cross-Reactive Bundibugyo Antibody Responses after Receipt of Licensed Ebola Vaccines — New England Journal of Medicine
📌 Key Facts
- On Thursday, August 27, 2026, Congo launched an Ebola vaccination campaign in Kisangani using the Ervebo vaccine.
- The outbreak has infected 5,713 people and killed 2,744 across six provinces, a confirmed-case fatality rate of about 48%.
- WHO has approved 70,000 Ervebo doses for Congo; 50,000 will go to frontline workers and 20,000 to a clinical trial on Bundibugyo Ebola.
- The campaign initially targets 14 health zones in Tshopo, Bas-Uele and Haut-Uele provinces, focusing on health workers and patient contacts.
📰 Source Timeline (1)
Follow how coverage of this story developed over time